Press Release Seraxis Announces FDA IND Allowance for Clinical Study of SR-02 Replacement Islets for Type 1 Diabetes admin October 15, 2024
In the news ENDPOINTS NEWS: Maryland biotech gets green light for stem cell-derived therapy for diabetes, aiming to compete with Vertex admin October 15, 2024
Press Release Seraxis wins grant from Maryland Stem Cell Research Fund to accelerate development of allogenetically compatible pancreatic islet replacement therapy for functional cure of T1D. admin June 14, 2024
Press Release Seraxis’ manufacturing suite completes GMP quality system audit ahead of SR-02 IND filing and transplantation of pancreatic clusters to patients with Type 1 Diabetes. admin January 4, 2024
Publication The transcription factors ISL-1 and MAFA, but not NKX6-1 Characterize a Stem-cell Derived Population of Endocrine Pancreatic Cells Capable of Controlling blood Glucose in Rodent Models of Diabetes. admin December 31, 2023
Press Release Seraxis Announces Publication of Preclinical Data for a Novel Islet Replacement Therapy and Clinical Candidate SR-02 for Insulin-Requiring Diabetes; Oral Presentation at IPITA. admin October 26, 2023
Press Release Seraxis to provide oral update on its pancreatic organoid candidate for functional cure of T1D at the 59th Annual Meeting of the EASD. admin September 28, 2023
Press Release Seraxis announces closing of second VC tranche and successful completion of preclinical studies of pancreatic organoids from Seraxis’ novel pancreas-derived stem cells. admin September 20, 2023
